Literature DB >> 19521957

Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays.

Meng Chen1, Yuanqing Ye, Hushan Yang, Pheroze Tamboli, Surena Matin, Nizar M Tannir, Christopher G Wood, Jian Gu, Xifeng Wu.   

Abstract

The identification of genetic aberrations may help understand the mechanisms of tumorigenesis and has important implications in diagnosis, prognosis and treatment. We applied Illumina's 317K high-density single nucleotide polymorphism (SNP) arrays to profile chromosomal aberrations in clear cell renal cell carcinoma (ccRCC) from 80 patients and analyzed the association of LOH/amplification events with clinicopathological characteristics and telomere length. The most common loss of heterozygosity (LOH) were 3p (69 cases) including 38 whole 3p arm losses, 30 large fragment LOH (spanning 3p21-36), and 1 interstitial LOH (spanning 3p12-14, 3p21-22, 3p24.1-24.2 and 3p24.3), followed by chromosome losses at 8p12-pter, 6q23.3-27, 14q24.1-qter, 9q32-qter, 10q22.3-qter, 9p13.3-pter, 4q28.3-qter and 13q12.1-21.1. We also found several smallest overlapping regions of LOH that contained tumor suppressor genes. One smallest LOH in 8p12 had a size of 0.29 Mb and only contained one gene (NRG1). The most frequent chromosome gains were at 5q (32 cases), including 10 whole 5q amplification, 21 large amplifications encompassing 5q32-ter and 1 focal amplification in 5q35.3 (0.42 Mb). The other common chromosome gains were 1q25.1-qter, 7q21.13-qter, 8q24.12-qter and whole 7p arm. Significant associations of LOH at 9p, 9q, 14q and 18q were observed with higher nuclear grade. Significant associations with tumor stage were observed for LOH at 14q, 18p and 21q. Finally, we found that tumors with LOH at 2q, 6p, 6q, 9p, 9q and 17p had significantly shorter telomere length than those without LOH. This is the first study to use Illumina's SNP-CGH array that provides a close estimate of the size and frequency of chromosome LOH and amplifications of ccRCC. The identified regions and genes may become diagnostic and prognostic biomarkers as well as potential targets of therapy.

Entities:  

Mesh:

Year:  2009        PMID: 19521957      PMCID: PMC2768265          DOI: 10.1002/ijc.24642

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  71 in total

Review 1.  Laparoscopic radical nephrectomy and minimally invasive surgery for kidney cancer.

Authors:  Nicolette K Janzen; Kent T Perry; Peter G Schulam
Journal:  Cancer Treat Res       Date:  2003

2.  Computer image analysis of comparative genomic hybridization.

Authors:  J Piper; D Rutovitz; D Sudar; A Kallioniemi; O P Kallioniemi; F M Waldman; J W Gray; D Pinkel
Journal:  Cytometry       Date:  1995-01-01

3.  A detailed deletion mapping of the short arm of chromosome 3 in sporadic renal cell carcinoma.

Authors:  K Yamakawa; R Morita; E Takahashi; T Hori; J Ishikawa; Y Nakamura
Journal:  Cancer Res       Date:  1991-09-01       Impact factor: 12.701

4.  Telomeric associations and loss of telomeric DNA repeats in renal tumors.

Authors:  K Holzmann; N Blin; C Welter; K D Zang; G Seitz; W Henn
Journal:  Genes Chromosomes Cancer       Date:  1993-03       Impact factor: 5.006

5.  Chromosome arm 8p and cancer: a fragile hypothesis.

Authors:  Daniel Birnbaum; José Adélaïde; Cornel Popovici; Emmanuelle Charafe-Jauffret; Marie-Joelle Mozziconacci; Max Chaffanet
Journal:  Lancet Oncol       Date:  2003-10       Impact factor: 41.316

6.  Frequent loss of heterozygosity on chromosome 14 occurs in advanced colorectal carcinomas.

Authors:  J Young; B Leggett; M Ward; L Thomas; R Buttenshaw; J Searle; G Chenevix-Trench
Journal:  Oncogene       Date:  1993-03       Impact factor: 9.867

7.  Allelic losses at chromosome 17p in human renal cell carcinoma are inversely related to allelic losses at chromosome 3p.

Authors:  O Ogawa; T Habuchi; Y Kakehi; M Koshiba; T Sugiyama; O Yoshida
Journal:  Cancer Res       Date:  1992-04-01       Impact factor: 12.701

8.  Telomere shortening in renal cell carcinoma.

Authors:  C Mehle; B Ljungberg; G Roos
Journal:  Cancer Res       Date:  1994-01-01       Impact factor: 12.701

9.  Mutations of the VHL tumour suppressor gene in renal carcinoma.

Authors:  J R Gnarra; K Tory; Y Weng; L Schmidt; M H Wei; H Li; F Latif; S Liu; F Chen; F M Duh
Journal:  Nat Genet       Date:  1994-05       Impact factor: 38.330

10.  Consistent chromosome 3p deletion and loss of heterozygosity in renal cell carcinoma.

Authors:  G Kovacs; R Erlandsson; F Boldog; S Ingvarsson; R Müller-Brechlin; G Klein; J Sümegi
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

View more
  35 in total

Review 1.  Emerging molecular classification in renal cell carcinoma: implications for drug development.

Authors:  Kathryn E Hacker; W Kimryn Rathmell
Journal:  Target Oncol       Date:  2010-07-20       Impact factor: 4.493

Review 2.  Telomere dynamics in mice and humans.

Authors:  Rodrigo T Calado; Bogdan Dumitriu
Journal:  Semin Hematol       Date:  2013-04       Impact factor: 3.851

3.  Histopathologic subtype-specific genomic profiles of renal cell carcinomas identified by high-resolution whole-genome single nucleotide polymorphism array analysis.

Authors:  Akira Yokomizo; Ken Yamamoto; Kenji Furuno; Masaki Shiota; Katsunori Tatsugami; Kentaro Kuroiwa; Seiji Naito
Journal:  Oncol Lett       Date:  2010-09-23       Impact factor: 2.967

Review 4.  Epidemiology and risk factors for kidney cancer.

Authors:  Wong-Ho Chow; Linda M Dong; Susan S Devesa
Journal:  Nat Rev Urol       Date:  2010-05       Impact factor: 14.432

5.  Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor.

Authors:  Xun Xu; Yong Hou; Xuyang Yin; Li Bao; Aifa Tang; Luting Song; Fuqiang Li; Shirley Tsang; Kui Wu; Hanjie Wu; Weiming He; Liang Zeng; Manjie Xing; Renhua Wu; Hui Jiang; Xiao Liu; Dandan Cao; Guangwu Guo; Xueda Hu; Yaoting Gui; Zesong Li; Wenyue Xie; Xiaojuan Sun; Min Shi; Zhiming Cai; Bin Wang; Meiming Zhong; Jingxiang Li; Zuhong Lu; Ning Gu; Xiuqing Zhang; Laurie Goodman; Lars Bolund; Jian Wang; Huanming Yang; Karsten Kristiansen; Michael Dean; Yingrui Li; Jun Wang
Journal:  Cell       Date:  2012-03-02       Impact factor: 41.582

6.  SCCRO3 (DCUN1D3) antagonizes the neddylation and oncogenic activity of SCCRO (DCUN1D1).

Authors:  Guochang Huang; Cameron Stock; Claire C Bommeljé; Víola B Weeda; Kushyup Shah; Sarina Bains; Elizabeth Buss; Manish Shaha; Willi Rechler; Suresh Y Ramanathan; Bhuvanesh Singh
Journal:  J Biol Chem       Date:  2014-10-27       Impact factor: 5.157

Review 7.  Iodothyronine deiodinases and cancer.

Authors:  A Piekiełko-Witkowska; A Nauman
Journal:  J Endocrinol Invest       Date:  2011-05-27       Impact factor: 4.256

8.  Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma.

Authors:  Blanka Kucejova; Samuel Peña-Llopis; Toshinari Yamasaki; Sharanya Sivanand; Tram Anh T Tran; Shane Alexander; Nicholas C Wolff; Yair Lotan; Xian-Jin Xie; Wareef Kabbani; Payal Kapur; James Brugarolas
Journal:  Mol Cancer Res       Date:  2011-07-28       Impact factor: 5.852

Review 9.  Telomere diseases.

Authors:  Rodrigo T Calado; Neal S Young
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

Review 10.  The structure and function of NKAIN2-a candidate tumor suppressor.

Authors:  Shan-Chao Zhao; Bo-Wei Zhou; Fei Luo; Xueying Mao; Yong-Jie Lu
Journal:  Int J Clin Exp Med       Date:  2015-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.